ABCL - AbCellera Biologics Director Trades Company's Stock | Benzinga
John Montalbano, Director at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on November 8, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Montalbano purchased 30,000 shares of AbCellera Biologics. The total transaction amounted to $137,400.
AbCellera Biologics shares are trading down 0.48% at $4.16 at the time of this writing on Thursday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important
Insider transactions shouldn't be used primarily to make an investing decision, however an insider ...